Loading…
Korean pharma/CDMO, part of Dong-A Socio Group, making its own generic drugs plus contract-manufacturing oligonucleotide APIs.
Korean pharma/CDMO, part of Dong-A Socio Group, making its own generic drugs plus contract-manufacturing oligonucleotide APIs.
Is paid per batch or under supply agreements by drug developers for making oligonucleotides, short strands of genetic material used as drugs, so revenue depends on when customers' drugs move from trials to commercial supply. Its own branded generics are a smaller, more domestic line.
Moat: narrow (process know-how, customer qualification). One of few global-scale oligonucleotide API manufacturers, a specialized, hard-to-replicate process.
Headquarters: Seoul, South Korea · Founded: 1959 · Employees: 780
Size ST Pharm (237690.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.12B, the 220th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩72,600 on 6 Nov 2026.
Performance Over six months the shares fell 52.4%, against -15.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 26.3% over the last twelve months (peer median +8.4%); the operating margin is 17.8% (peer median 7.7%).
Valuation It trades at 27.9× forward earnings against a peer median of 24.6× (4th most expensive of 11).
Capital Return on invested capital runs 2.8 points above its cost of capital (6.0% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩402B | ₩332B | ₩274B | ₩285B | ₩249B |
| Revenue growth | — | +21% | -4% | +14% | — |
| Gross profit | n/a | ₩129B | ₩90.6B | ₩107B | ₩83.3B |
| EBITDA | n/a | ₩84.4B | ₩53.0B | ₩54.1B | ₩35.5B |
| Net income | ₩60.1B | ₩55.0B | ₩34.7B | ₩19.6B | ₩18.0B |
| Free cash flow | n/a | -₩29.6B | ₩30.2B | -₩41.6B | -₩53.0B |
| Capital expenditure | n/a | ₩47.3B | ₩83.2B | ₩43.4B | ₩60.7B |
| Total debt | n/a | ₩78.7B | ₩118B | ₩192B | ₩135B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 237690.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.7% | -6.8% | 4th lowest of 21 |
| 6-month return | -52.4% | -15.2% | lowest of 21 |
| Distance from 52-week high | -57.8% | -35.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | +26.3% | +8.4% | 6th highest of 19 |
| Operating margin | 17.8% | 7.7% | 6th highest of 19 |
| Forward P/E | 27.9× | 24.6× | 4th most expensive of 11 |
| ROIC minus cost of capital | +2.8 pp | -0.2 pp | 6th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |